Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo Nordisk Earnings Are Here. Wegovy Sales Beat Estimates for Weight Loss Drug.
Novo Nordisk posted solid quarterly results Wednesday before the market open.Sales came in at 71.3 billion Danish crowns ($10.3 billion) and diluted earnings per share of DKK 6.12 in the third quarter.
Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs, as it reported revenue and operating profit broadly in line with analysts’ expectations. The maker of the blockbuster Ozempic and Wegovy drugs has benefited in recent years from huge demand for its products.
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Novo Nordisk’s Blockbuster Wegovy Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023.
WebMD6d
Weight Loss Drugs May Be a New Alternative to Knee Replacements
A new study suggests that weekly self-injections of the weight loss drug semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.
BioPharma Dive2d
Viking data provide latest test of oral obesity drug potential
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
Viking Therapeutics' New Weight Loss Pill Shows Promising Results
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
But after gaining more than 20 pounds during undergraduate and graduate school and feeling unhappy with her weight, the ...
The i on MSN2d
Why you still have to exercise if you’re using weight loss jabs
Online pharmacies are the only way to get weight loss injections for most people, but doctors are concerned some firms do not ...
News Nation on MSN5d
Weight-loss drug ingredient could help knee pain: Study
( NewsNation) — An active ingredient in some weight-loss drugs could help people suffering from osteoarthritis knee pain, a ...
UK regulator tells doctors to watch out for obesity injection misuse
The UK's drug safety regulator is asking doctors to be alert for patients who may be misusing obesity injections, such as ...
Life Science Leader6d
A Bioethicist Weighs In On Obesity Drugs
Anne Zimmerman, editor-in-chief of the Columbia University online journal, <a href=" target="_blank">Voices in Bioethics ...
Experts weigh in on adolescent access to weight loss drugs
Some adults are seeing results in losing weight or reducing their risk of diabetes and heart disease using injectables, such ...